PMGC Holdings ELAB
NASDAQ ELAB
$6.66 +0.56 (+9.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

PMGC Holdings (ELAB) Cost of Revenue (2022 - 2026)

PMGC Holdings (ELAB) posted Cost of Revenue of $451520.0 for Q1 2026, up 129.37% sequentially from $196852.0 in Q4 2025, and up 1378.94% YoY from $30530.0 in Q1 2025.

PMGC Holdings (ELAB) Cost of Revenue (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Cost of Revenue for 5 years, with the latest figure at $451520.0 in Q1 2026.

  • Quarterly Cost of Revenue rose 1378.94% year-over-year to $451520.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $856290.0 (up 61.01% YoY) and the FY2025 annual result came in at $404770.0, down 39.6% from the prior year.
  • Cost of Revenue advanced to $451520.0 in Q1 2026 per ELAB's latest filing, from $196852.0 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $194.4 million in Q3 2022 and troughed at -$273.2 million in Q4 2022.
  • A 5-year average of -$5.5 million and a median of $178710.0 in 2023 frame the typical range for Cost of Revenue.
  • The sharpest annual moves came in 2023 and 2026: Cost of Revenue plunged 99.9% in 2023, then surged 1378.94% in 2026.
  • Over 5 years, Cost of Revenue stood at -$273.2 million in 2022, then soared by 100.09% to $236893.0 in 2023, then fell by 14.97% to $201434.0 in 2024, then declined by 2.27% to $196852.0 in 2025, then jumped by 129.37% to $451520.0 in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods registered $451520.0, $196852.0, and $207918.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 489.20 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 360.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 145.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 93.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 174.53 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 298.26 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 387.98 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 67.21 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 PMGC Holdings 31.22 Mn 12.43 Mn 385,691.00 920,919.00

Historic Data

Download Data
DateValue
Mar 31, 2026 451,520.00
Mar 31, 2026 451,520.00
Dec 31, 2025 196,852.00
Dec 31, 2025 196,852.00
Sep 30, 2025 207,918.00
Sep 30, 2025 207,918.00
Mar 31, 2025 30,530.00
Mar 31, 2025 30,530.00
Dec 31, 2024 201,434.00
Dec 31, 2024 201,434.00
Sep 30, 2024 133,578.00
Sep 30, 2024 133,578.00
Jun 30, 2024 166,274.00
Jun 30, 2024 166,274.00
Mar 31, 2024 168,911.00
Mar 31, 2024 168,911.00
Dec 31, 2023 236,893.00
Dec 31, 2023 236,893.00
Sep 30, 2023 188,509.00
Sep 30, 2023 188,509.00